Detection Performance of Circulating MicroRNA-210 for Renal Cell Carcinoma: a Meta-Analysis

Background: Renal cell carcinoma (RCC) is the most common neoplasm of the adult kidney. miR-210 was a known oncogene with tumor-promoting effects in many types of cancer. This meta-analysis aimed to evaluate the potential diagnostic value of circulating miR-210. Methods: Relevant literature was collected from PubMed and Embase. Sensitivity, specificity, and diagnostic odds ratio (DOR) for miR-210 in the diagnosis of RCC were pooled using random effects models. Summary receiver operating characteristic (SROC) curve analysis and the area under the curve (AUC) were used to estimate the overall test performance. Results: This meta-analysis included seven studies with a total of 570 RCC patients and 415 healthy controls. For miR-210, the pooled sensitivity, specificity, and DOR to predict RCC patients were 0.74 (95% confidence interval [CI]: 0.70 - 0.77), 0.76 (95% CI: 0.71 - 0.80) and 8.81 (95% CI: 5.31 - 14.57), respectively. In addition, the AUC of miR-210 for the diagnosis of RCC is 0.81. Conclusions: MiR-210 might be a potential novel biomarker in the diagnosis of renal cell carcinoma.